| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 10/14/2004 | WO2004087124A1 Compounds having serotonin 5-ht17 receptor antagonist activity and muscarinic m4 receptor agonist activity and their use in the treatment of psychotic disorders |
| 10/14/2004 | WO2004087116A2 Drug combination for motor dysfunction in parkinson's disease |
| 10/14/2004 | WO2004087105A1 Combination formulations of platinum agents and fluoropyrimidines |
| 10/14/2004 | WO2004087094A2 Nano-sized vehicles transporting a therapeutic agent and at least one drug resistance modulator for the treatment of multi drug resistance |
| 10/14/2004 | WO2004086880A1 Sodium chloride-containing foods and drinks |
| 10/14/2004 | WO2004060379A3 Pharmaceutical compositions comprising an antibacterial agent nd antifungal agent and a nitroimidazole for the treatment and prevention of genitourinary infections and their extragenital complications |
| 10/14/2004 | WO2004052346A8 Pharmaceutical compositions containing indistinguishable drug components |
| 10/14/2004 | WO2004052315A3 Tyrosine kinase inhibitors |
| 10/14/2004 | WO2004039311A3 Human vps4a and vps4b functions in viral budding |
| 10/14/2004 | WO2004024063A3 Compositions and methods for the diagnosis and treatment of tumor |
| 10/14/2004 | WO2004021010A3 Method of diagnosing colon and gastric cancers |
| 10/14/2004 | WO2004017916A3 Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition |
| 10/14/2004 | WO2003101395A3 Formulations for amylin agonist peptides |
| 10/14/2004 | WO2003065985A3 Uses of mammalian cytokine; related reagents |
| 10/14/2004 | US20040204673 Modular infusion device and method |
| 10/14/2004 | US20040204578 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 10/14/2004 | US20040204565 Use of multivalent chimeric peptide-loaded, MHC/IG molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses |
| 10/14/2004 | US20040204484 Therapeutic mixture useful in inhibiting lesion formation after vascular injury |
| 10/14/2004 | US20040204481 Activation of natural killer cells by adenosine A3 receptor agonists |
| 10/14/2004 | US20040204480 Anti-cancer combinations |
| 10/14/2004 | US20040204477 For use as antiproliferative agents |
| 10/14/2004 | US20040204472 Administering to the subject a Cox-2 inhibitor for therapy and prophylaxis of obesity and obesity-related complications |
| 10/14/2004 | US20040204471 Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents |
| 10/14/2004 | US20040204469 Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders |
| 10/14/2004 | US20040204468 Clear odorless liquid gel |
| 10/14/2004 | US20040204467 Use of 5HT3-receptor-antagonists |
| 10/14/2004 | US20040204458 Use of Lck inhibitors for treatment of immunologic diseases |
| 10/14/2004 | US20040204456 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| 10/14/2004 | US20040204444 Combination of organic compounds |
| 10/14/2004 | US20040204441 Nasal delivery of apomorphine |
| 10/14/2004 | US20040204438 such as N-[4-(4-amino-1H-imidazol[4,5-c]quinolin-1-yl)butyl]-5-(dimethylamino)-naphthalenesulfonamide; for induction of biosynthesis of cytokines; immunomodulators; antineoplastic agents |
| 10/14/2004 | US20040204435 Alternating treatment with topoisomerase I and topoisomerase II inhibitors |
| 10/14/2004 | US20040204429 Reversible inhibitors of SAH hydrolase and uses thereof |
| 10/14/2004 | US20040204428 Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligandsof the adenosine a2a receptor and their use as medicaments |
| 10/14/2004 | US20040204425 Sodium channel blockers |
| 10/14/2004 | US20040204416 Pharmaceutical composition for the treatment of CNS and other disorders |
| 10/14/2004 | US20040204413 Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant |
| 10/14/2004 | US20040204411 Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| 10/14/2004 | US20040204403 Pharmaceutical composition comprising ibuprofen and prochlorperazine |
| 10/14/2004 | US20040204401 Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions |
| 10/14/2004 | US20040204399 Aerosolized decongestants for the treatment of sinusitis |
| 10/14/2004 | US20040204393 Aromatase inhibition to enhance assisted reproduction |
| 10/14/2004 | US20040204391 Applying onto healed wound a composition comprising a fluid, film-forming carrier, and subsequently hardening the carrier into a tangible membrane juxtaposed to the healed wound thereby reducing scarring or improving the appearance thereof |
| 10/14/2004 | US20040204390 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist |
| 10/14/2004 | US20040204388 incubating SV2 protein or fragment with levetiracetam or an analog or derivative thereof and a potential binding partner and determining if the potential binding partner modulates the binding of levetiracetam to the SV2 protein |
| 10/14/2004 | US20040204375 Gene delivery compounds |
| 10/14/2004 | US20040204372 Synergistic mixture of piperacillin and tazobactam; controlling bacteria infections |
| 10/14/2004 | US20040204364 Peptides for activation and inhibition of deltaPKC |
| 10/14/2004 | US20040204361 Kdel receptor inhibitors |
| 10/14/2004 | US20040204347 administering an effective amount of an inhibitor of the interaction of glutamate with the alpha -amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptor complex to treat demyelinating disorders |
| 10/14/2004 | US20040204341 Nr2b receptor antagonists for the treatment or prevention of migraines |
| 10/14/2004 | US20040204339 Anticancer agents; administering dosage of Dna methylation antagonist such as decitabine and enzyme inhibitor |
| 10/14/2004 | US20040204338 Acetyl-coenzyme a carboxylase 2 as a target in the regulation of fat burning, fat accumulation, energy homeostasis and insulin action |
| 10/14/2004 | US20040203146 Composite scaffolds and methods using same for generating complex tissue grafts |
| 10/14/2004 | US20040203144 Using calcium-activated chloride channels (CLCA) to identify modulators for treatment of bronchitis, asthma, cystic fibrosis, chronic obstructive pulmonary disease (COPD) and bronchiectasis |
| 10/14/2004 | US20040203128 Use of PP2A phosphatase modulators in the treatment of mental disorders |
| 10/14/2004 | US20040203111 UDP-N-acetylglucosamine: galactose-B1,3-N-acetylgalactosamine-a-R/ (GlcNAc to GalNAc) B1-6 N- acetylglucosaminyltransferase, C2GnT3 |
| 10/14/2004 | US20040203105 for drug screening emzyme inhibitors using genetically engineered animal models; for anticancer agents |
| 10/14/2004 | US20040203104 for drug screening enzyme inhibitors; genetic engineering; comprising subjecting the sample to a polymerase chain reaction, a northern hybridization assay or an in situ hybridization assay |
| 10/14/2004 | US20040203097 Kinases and phosphatases |
| 10/14/2004 | US20040203092 UDP-N-acetylglucosamine:galactose-beta1,3-N-acetylgalactosamine-alpha-R/ (GlcNAc to GalNAc) beta1-6 N-acetylglucosaminyltransferase, C2GnT3 |
| 10/14/2004 | US20040203087 screening gene expression inhibition via incubating mrna, determining expression in presence of test compound, then comparing levels; gene knockout |
| 10/14/2004 | US20040203054 Use of SLIM3 for binding to molecules |
| 10/14/2004 | US20040203045 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases |
| 10/14/2004 | US20040203014 Neurotransmisson-associated proteins |
| 10/14/2004 | US20040202899 alumina, silica or titania, an element or compound of platinum, palladium, iridium or rhodium; colloidal dispersions are mixed and blended with synthetic polymers and spun into filaments or hollow fibers; clothing and bedding; anticoagulants |
| 10/14/2004 | US20040202726 liquid carrier comprising: water; potassium chloride; and a penetrant enhancer for enhancing the penetration of the potassium chloride into the skin. |
| 10/14/2004 | US20040202725 Compositions for the treatment of pilosebaceous gland inflammations comprising aluminium fluoride |
| 10/14/2004 | US20040202723 hydrolyzing titanium alkoxide in a reverse micelle solution of highly-dispersed nano-droplets of an organic continuous phase, a nonionic surfactant, and water to form a TiO2-containing solution; dip coating it on a substrate; drying and calcining; used for for killing bacteria and viruses in UV radiation |
| 10/14/2004 | US20040202720 Delivery of immune response modifier compounds using metal-containing particulate support materials |
| 10/14/2004 | US20040202719 cross-linked polymer encapsulating the therapeutic agent; degradation rate of the cross-linked polymer is correlated with a local concentration of an indicator, and the therapeutic agent is released as the cross-linked polymer degrades. |
| 10/14/2004 | US20040202705 including as a permeation enhancer fatty acids, fatty acid esters, fatty alcohols, amides, pyrrolidones, glycerol triesters, and/or terpenes and their salts; provides a huperzine blood plasma level of 0.1 - 30 mg/ml |
| 10/14/2004 | US20040202702 Method and composition for the treatment of scars |
| 10/14/2004 | US20040202699 Textile for weight reduction |
| 10/14/2004 | US20040202681 Process for preparing pharmaceutical formulations using supercritical fluids |
| 10/14/2004 | US20040202656 Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders |
| 10/14/2004 | US20040202617 Delivery of opioids through an inhalation route |
| 10/14/2004 | US20040200431 Method for reducing bacterial contamination and infectious diseases in livestock and other animals |
| 10/14/2004 | DE20315266U1 Powdered laxative composition based on plantago seeds and sennoside compounds, also containing polygalactomannan to facilitate suspension in water and improve activity |
| 10/14/2004 | DE10295684T9 Verfahren zum spezifischen Hemmen von Histon-Deacetylase-4 Method for the specific inhibition of histone deacetylase 4 |
| 10/14/2004 | CA2527126A1 Nano-sized vehicles transporting a therapeutic agent and at least one drug resistance modulator for the treatment of multi drug resistance |
| 10/14/2004 | CA2521274A1 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders |
| 10/14/2004 | CA2521052A1 Nitric oxide in treatment of inflammation |
| 10/14/2004 | CA2520932A1 Dosage forms comprising ag013736 |
| 10/14/2004 | CA2517487A1 Inhibitors of phosphodiesterases in infertility |
| 10/14/2004 | CA2464175A1 Methods and compositions for modulating proteins modified in preconditioning against ischemia/hypoxia |
| 10/13/2004 | EP1466917A1 Method for making peptide boronic acids and acids obtainable thereby |
| 10/13/2004 | EP1466916A1 Peptide boronic acids useful in making salts thereof |
| 10/13/2004 | EP1466902A1 Androgen receptor antagonists |
| 10/13/2004 | EP1466649A1 Pharmaceutical composition containing artificial oxygen carrier |
| 10/13/2004 | EP1466641A1 Treatment of pulmonary vasoconstriction and asthma |
| 10/13/2004 | EP1466624A1 Drug for regenerating tissue and vessel and method therefor |
| 10/13/2004 | EP1466615A1 Pharmaceutical composition |
| 10/13/2004 | EP1466607A1 Compositions for the treatment of primary and metastatic neoplastic diseases using arsenic compounds in combination with all-trans retinoic acid |
| 10/13/2004 | EP1466602A1 Organ fibrosis inhibitors |
| 10/13/2004 | EP1466601A2 Prevention of migraine recurrence |
| 10/13/2004 | EP1466598A2 PDE-IV inhibitors |
| 10/13/2004 | EP1466175A2 SPHKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 10/13/2004 | EP1466009A2 Highly sensitive and continuous protein-tyrosine-phosphatase (ptpase) test using 6.8 difluoro-4-methyl-umbelliferylphosphate |
| 10/13/2004 | EP1465998A2 Single nucleotide polymorphisms predicting cardiovascular disease and medication efficacy |